NTR heads into its August earnings window with a notable insider buying cluster at its back and short sellers quietly stepping away from the name.
The most compelling angle this week is what happened inside the company on May 8. Seven executives bought shares on the same day — CEO Ken Seitz picked up 3,900 shares at CAD 94.52, Independent Director Aaron Regent added 14,490 shares for roughly USD 999K, and an Executive Vice President bought 2,400 shares. The CFO, Mark Thompson, has since added three more smaller tranches — most recently on June 9 at CAD 92.06. Net insider buying over the past 90 days totals over 114,000 shares with a combined value near USD 7.2 million. That kind of coordinated cluster, spanning the CEO, CFO, and multiple senior officers, is a meaningful signal of internal conviction at current price levels.
The short side of the ledger reinforces that picture. Bears are not pressing the name. Short interest has dropped roughly 13% over the past week to just 0.56% of the free float — a level so low it barely registers as a headwind. Borrow costs have ticked up about 28% on the week to 0.59%, but in absolute terms that remains exceptionally cheap. More telling still, availability is extraordinarily loose — over 7,700% of current short interest, meaning there are more than 432 million shares available to borrow against a position of under 3 million shorted. The ORTEX short score has drifted down from 27.2 in late May to 26.8 now, consistent with waning short-side interest. Positioning looks unambiguously light on the bear side.
The valuation backdrop is modest rather than stretched. NTR trades at roughly 11.5x trailing earnings and 6.5x EV/EBITDA, with both multiples broadly flat on the week. Price-to-book has compressed about 9% over the past month to 1.16x, which partly reflects the stock's 4% pull-back over the same period. The EPS momentum factor scores are constructive — 74 on the 30-day reading and 62 on 90 days — while the dividend score ranks in the 92nd percentile, reflecting Nutrien's history as a reliable income name. The forward earnings growth score is a drag at just 13, consistent with analyst caution on the fertilizer pricing cycle. Analyst data in the system is stale and should not be relied upon for current price targets.
Among peers, the week's price action was mixed. MOS surged over 7% on Friday and gained 2% on the week. IPI added 3.4% over the same stretch. CF fell 3.5% on the week despite a strong Friday. YAR and SDF were the laggards, down 4.8% and 3.8% respectively. NTR's 1% weekly gain sits near the middle of the peer group — it neither led nor lagged — but its year-to-date outperformance remains intact versus the broader fertilizer space. The institutional picture is broadly supportive: BlackRock lifted its position by over 1 million shares to 5.2% of the company as of end-May, and Capital Research added 3.1 million shares. Arrowstreet trimmed by 1.8 million shares — the one meaningful reduction in the top-15 holder list.
The next hard catalyst is the Q1 results due August 5. The two most recent earnings prints both delivered sharp one-day losses — around 7% and 11% respectively — so the market's skittishness around Nutrien reporting days is well established. Whether the insider buying cluster signals management confidence ahead of that release, or simply reflects routine stock plan purchases, is what the market will be weighing between now and then.
See the live data behind this article on ORTEX.
Open NTR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
